News & Events
Letter to stakeholders regarding the implementation of safety features under the Falsified Medicines Directive 2011/62/EU
October 30, 2018
A key measure to address falsification in the EU and protect the legal supply chain of medicines is an end-to-end verification system introduced by the Falsified Medicines Directive (FMD). The end-to-end verification is a medicines authentication system including mandatory safety features and a repository that stores information on each individual pack.
The new rules will become applicable in the EU and EEA on 9 February 20192. From this date, prescription medicines3 placed on the EU market will need to carry a unique identifier (UI) and anti-tampering device (ATD), in acordance with the FMD and the Commision Delegated Regulation (EU) 2016/161.4 The repository system, currently being set up by stakeholders and consisting of a European hub and national databases, will also need to be operational by 9 February 2019.
Read the letter in full in the PDF document attached below.
If you have any questions or need some information, we will gladly communicate with you via or via the following contact form. To successfully reply to your message, please, fill out all contact form fields and enter the summation result into the 'captcha' field to protect against spam messages:
© 2018 HOPAL
Croatian Medicines Veryfication Organization
Radnička 80, 10000 Zagreb, Croatia
T +385 (0)1 5625 759
F +385 (0)1 5625 760